Nature Communications | KRAS Mutation-Specific Lysosome-Targeting Protein Degradation Based on a Lipoprotein-Mimetic Nanoplatform

This study offers a novel therapeutic strategy for addressing undruggable targets in KRAS mutant tumors, particularly through the mechanism of mutation-specific degradation via macropinocytosis. This approach provides direct inspiration for tumor immunotherapy and the development of drugs targeting undruggable sites.

 

Literature Overview

The article titled "A lipoprotein-biomimetic nanoplatform for oncogenic KRAS mutation-specific lysosome-targeting protein degradation," published in Nature Communications, systematically explores a novel nanoplatform named KRASTAC. By mimicking lipoprotein structures and leveraging the unique macropinocytosis metabolic dependency of KRAS-mutant tumor cells, this platform achieves precise lysosomal degradation of specific oncogenic proteins.

Background Knowledge

The core challenge in current tumor therapy lies in distinguishing malignant cells from normal cells within the same lineage. Existing technologies, such as Lysosome-Targeting Chimeras (LYTAC), often lack cell specificity due to the widespread expression of their target receptors, leading to off-target toxicity. KRAS, the most common oncogenic driver gene, presents a typical undruggable target: its mutant forms lack traditional small-molecule binding pockets and are often accompanied by the abnormal overexpression of membrane proteins like EGFR and PD-L1, creating an immunosuppressive microenvironment. Current therapies struggle to efficiently clear these proteins at low concentrations and cannot distinguish between mutant and wild-type cells. This study addresses this gap by exploiting the metabolic dependency of KRAS-mutant cells on macropinocytosis. It designs a lipid nanoparticle modified with Apolipoprotein E (APOE) and conjugated with specific antibodies via click chemistry. This constructs the KRASTAC platform, capable of specifically recognizing and internalizing target proteins into lysosomes for degradation, thereby solving the challenge of mutation-specific degradation.

 

 

Research Methods and Core Experiments

The authors constructed a biomimetic nanoplatform formed by APOE adsorbed onto the surface of lipid nanoparticles (LNPs), conjugated with anti-PD-L1 or anti-EGFR antibodies via click chemistry. Initial experiments utilized biotinylated LNPs and a streptavidin model to verify the macropinocytosis-dependent internalization and lysosomal localization of the nanoparticles in various KRAS-mutant cell lines (e.g., HCT116, NCI-H460) and wild-type controls using flow cytometry and confocal microscopy. Subsequently, the team evaluated the degradation efficiency of KRASTAC against PD-L1 and EGFR in vitro, finding that it achieved nearly 70% protein degradation within 9 hours at a low concentration of 2.5 nM, with no effect on wild-type cells. Mechanistic studies employing a genome-wide CRISPR-Cas9 screen identified LDLR and SLC35B2 as key receptors mediating this process, a finding validated using gene-knockout cell lines and inhibitors. In vivo experiments utilized syngeneic mouse models (MC38) and humanized xenograft models. Live imaging, Western Blot, and immunohistochemistry confirmed the specific accumulation of KRASTAC in KRAS-mutant tumors and its protein degradation efficacy.

Key Conclusions and Perspectives

• The KRASTAC platform can efficiently degrade PD-L1 and EGFR within 9 hours at extremely low antibody concentrations (2.5 nM), significantly outperforming existing LYTAC or nanosphere platforms, thus enabling low-dose administration.
• The mutation-specific degradation mechanism of this platform relies on macropinocytosis mediated by the high expression of LDLR and SLC35B2 in KRAS-mutant cells, revealing a coupling relationship between metabolic reprogramming and protein degradation pathways.
• In vivo experiments confirmed that KRASTAC-induced PD-L1 degradation significantly increases the infiltration and activation of CD8+ T cells in the tumor microenvironment, reversing the immunosuppressive state and achieving durable anti-tumor effects in KRAS-mutant tumor models.
• Through modular design, the platform can be flexibly adapted to different antibodies (e.g., anti-HER2, anti-VEGF), demonstrating broad target applicability and providing technical support for multi-target combination therapy strategies.

Research Significance and Prospects

This discovery provides a novel mutation-specific delivery strategy for the drug development field, promising to solve the problem of off-target distribution of traditional antibody drugs in normal tissues, particularly for KRAS-mutant-driven refractory tumors. In terms of clinical monitoring, this study suggests that the expression levels of LDLR and SLC35B2 could serve as biomarkers to predict KRASTAC efficacy. Furthermore, this strategy offers new tools for disease modeling. In the future, combining this approach with gene editing technologies could enable the construction of more precise mutation-specific protein degradation models, accelerating the translation from laboratory to clinic.

 

 

Conclusion

This study successfully developed a lipoprotein-mimetic KRASTAC nanoplatform that ingeniously exploits the unique macropinocytosis metabolic vulnerability of KRAS-mutant tumor cells to achieve precise, efficient, and mutation-specific lysosomal degradation of oncogenic proteins. This breakthrough not only overcomes the bottleneck of lacking cell selectivity in traditional targeted protein degradation technologies but also opens a new pathway for treating KRAS-mutant-associated cancers. By specifically clearing immune checkpoint molecules such as PD-L1, the platform effectively reshapes the tumor immune microenvironment, demonstrating potent anti-tumor potential. From laboratory to clinical translation, the KRASTAC platform lays a solid foundation for the care systems of related diseases, signaling a future shift in cancer treatment towards a higher-precision, lower-toxicity era of mutation-specific targeting, bringing new hope to countless patients with refractory tumors.

 

Hang Yang, Xinyi Zhou, Jiafeng Wang, Quan Zhou, and Kefeng Ding. A lipoprotein-biomimetic nanoplatform for oncogenic KRAS mutation-specific lysosome-targeting protein degradation. Nature Communications.